Chris Jones, a 68-year-old lung cancer patient from Merseyside, has become the first person globally to receive a personalized vaccine in a clinical trial at the Clatterbridge Cancer Centre. The vaccine uses synthetic 'doggybone' DNA mapped from her own tumour to prevent immunotherapy resistance, which affects half of advanced lung cancer patients. Led by Professors Christian Ottensmeier and Natalia Savelyeva, the highly coordinated trial involves multiple UK organizations and will monitor 10 patients over 24 weeks.
Story comments
Loading comments…